ONS-5010/LYTENAVA will win FDA approval for neovascular age-related macular degeneration by August 12, 2026. The FDA accepted Outlook Therapeutics' resubmitted BLA on June 16, 2026 and set a PDUFA target action date of July 29, 2026 under a Class 1 review, and the agency's Office of New Drugs earli…